Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association

Point of Care Marketing Association

Allscripts’ business unit Veradigm announced today Veradigm has joined the Point of Care Marketing Association (POCMA), a nonprofit group that works to promote the Point of Care (POC) channel through education and advocacy:

  • The first EHR marketing solution to be accepted as a POCMA member is Veradigm Digital Health Media.
  • The board of directors of the POCMA now includes Stuart Green, senior vice president and general manager of Veradigm.

In order to improve patient healthcare outcomes, POCMA promotes the efficient use of the point of care communication channel. Members of the nonprofit point of care industry association collaborate closely with stakeholders from the brand, agency, and provider communities to promote the channel’s positive effects and advocate for the channel’s continued growth as an essential and cutting-edge area of healthcare marketing.

“POCMA is excited to have Veradigm as a member and the first within the EHR landscape”, “Veradigm’s platform of reaching HCPs in their workflow makes them an excellent resource for the association and its members. We look forward to their insights and involvement as we grow the POC industry.”

Nicole Divinagracia, Executive Director, POCMA.


“At Veradigm, we share in POCMA’s goal of raising healthcare providers’ awareness through innovative point of care marketing channels”, “With our membership, we look forward to contributing to the establishment of industry best practices and building connections with other point-of-care industry leaders and influencers.”

Stuart Green, Senior Vice President & General Manager, Veradigm.

Next Post

FDA Approves First Gene Therapy to Treat Adults with Hemophilia B

Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy, has been approved by the U.S. Food and Drug Administration for the treatment of adults with Haemophilia B (congenital factor IX deficiency) who are currently receiving Factor IX prophylaxis therapy, have experienced recent or past life-threatening hemorrhage, or have had recurrent, […]
Hemophilia B